Roche’s Foundation Medicine agreed to acquire Saga Diagnostics for up to $595 million, aiming to expand its cancer molecular residual disease (MRD) diagnostics portfolio. The deal adds Saga’s Pathlight platform, which uses whole-genome sequencing plus digital PCR to track structural variants for MRD detection. Foundation Medicine said it will leverage Roche’s sequencing and Digital LightCycler PCR capabilities to develop more decentralized MRD testing globally. Saga’s Pathlight is already available in the US for breast and colorectal MRD and is covered by Medicare for certain early-stage breast cancer recurrence monitoring. The acquisition underscores how MRD has become a strategic battleground for large diagnostics platforms—moving from research testing into scalable, clinically deployed workflows.